Bourgin Mélanie, Labarthe Simon, Kriaa Aicha, Lhomme Marie, Gérard Philippe, Lesnik Philippe, Laroche Béatrice, Maguin Emmanuelle, Rhimi Moez
Micalis Institute, Université Paris-Saclay, INRAE, AgroParisTech, Jouy-en-Josas, France.
Université Paris-Saclay, INRAE, MaIAGE, Jouy-en-Josas, France.
Front Microbiol. 2020 Jun 10;11:1121. doi: 10.3389/fmicb.2020.01121. eCollection 2020.
High blood cholesterol levels are often associated with cardiovascular diseases. Therapeutic strategies, targeting different functions involved in cholesterol transport or synthesis, were developed to control cholesterolemia in human. However, the gut microbiota is also involved in cholesterol regulation by direct biotransformation of luminal cholesterol or conversion of bile salts, opening the way to the design of new strategies to manage cholesterol level. In this report, we developed for the first time a whole-body human model of cholesterol metabolism including the gut microbiota in order to investigate the relative impact of host and microbial pathways. We first used an animal model to investigate the ingested cholesterol distribution . Then, using bacterial growth experiments and metabolite measurements, we modeled the population dynamics of bacterial strains in the presence of cholesterol or bile salts, together with their bioconversion function. Next, after correct rescaling to mimic the activity of a complex microbiota, we developed a whole body model of cholesterol metabolism integrating host and microbiota mechanisms. This global model was validated with the animal experiments. Finally, the model was numerically explored to give a further insight into the different flux involved in cholesterol turn-over. According to this model, bacterial pathways appear as an important driver of cholesterol regulation, reinforcing the need for development of novel "bacteria-based" strategies for cholesterol management.
高血胆固醇水平常与心血管疾病相关。人们开发了针对胆固醇转运或合成中不同功能的治疗策略,以控制人体的胆固醇血症。然而,肠道微生物群也通过对肠腔胆固醇的直接生物转化或胆汁盐的转化参与胆固醇调节,为设计控制胆固醇水平的新策略开辟了道路。在本报告中,我们首次开发了一个包括肠道微生物群的人体胆固醇代谢全身模型,以研究宿主和微生物途径的相对影响。我们首先使用动物模型研究摄入胆固醇的分布。然后,通过细菌生长实验和代谢物测量,我们模拟了存在胆固醇或胆汁盐时细菌菌株的种群动态及其生物转化功能。接下来,在正确重新缩放以模拟复杂微生物群的活性后,我们开发了一个整合宿主和微生物群机制的胆固醇代谢全身模型。该整体模型通过动物实验得到验证。最后,对该模型进行数值探索,以进一步深入了解胆固醇周转中涉及的不同通量。根据该模型,细菌途径似乎是胆固醇调节的重要驱动因素,这进一步凸显了开发新型“基于细菌”的胆固醇管理策略的必要性。